Annovis Bio Inc (ANVS)
NYSE:ANVS
Want to see ANVS full AI Analyst Report?
ANVS Stock Chart & Stats
$1.87
-$0.04(-0.79%)
At close: 4:00 PM EST
$1.87
-$0.04(-0.79%)
Day’s Range― - ―
52-Week Range$1.54 - $5.50
Previous CloseN/A
Volume368.97K
Average Volume (3M)1.25M
Market Cap
$61.32M
Enterprise Value$23.55M
Total Cash (Recent Filing)$14.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Aug 18, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding34,646,870
10 Day Avg. Volume1,460,153
30 Day Avg. Volume1,246,680
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$12.50Price Target Upside568.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Lead Asset (buntanetap) In Phase 3Having a lead small-molecule candidate in Phase 3 materially reduces early-stage science risk and focuses corporate resources on a single registrational program. Successful execution of Phase 3 can structurally de-risk value creation versus preclinical assets and attract partners or non-dilutive funding.
Debt-free Balance SheetA reported absence of debt lowers fixed financial obligations and bankruptcy risk, giving management flexibility to time financing and allocate cash to clinical programs. For a cash-burning biotech, no debt improves strategic optionality and reduces the need for restrictive covenants.
Proven Access To Public Capital MarketsSuccessful recent equity and registered direct offerings demonstrate the company can tap public markets to fund costly Phase 3 programs. This structural access extends runway and supports trial continuity, enabling advancement of the lead asset while management seeks longer-term financing or partnerships.
Bears Say
No Revenue; Persistent Operating LossesZero operating revenue and sustained losses mean the company cannot self-fund development and must rely on external capital. Over months this raises execution risk if markets tighten, increases probability of dilutive financings, and limits reinvestment into programs without outside funding.
Worsening, Volatile Cash BurnDeepening and volatile cash outflows impair runway predictability and complicate trial planning. Structural volatility in free cash flow weakens the company's ability to forecast financing needs, increasing the chance of unexpected dilutive raises or program delays that can erode long-term shareholder value.
Reliance On Dilutive Equity FinancingsFrequent equity offerings structurally dilute existing holders and signal dependence on market funding rather than internal cash generation. Over the medium term this reduces per-share upside for investors and can limit ability to secure favorable partnership terms or non-dilutive capital.
Annovis Bio News
ANVS FAQ
What was Annovis Bio Inc’s price range in the past 12 months?
Annovis Bio Inc lowest stock price was $1.54 and its highest was $5.50 in the past 12 months.
What is Annovis Bio Inc’s market cap?
Annovis Bio Inc’s market cap is $61.32M.
When is Annovis Bio Inc’s upcoming earnings report date?
Annovis Bio Inc’s upcoming earnings report date is Aug 18, 2026 which is in 68 days.
How were Annovis Bio Inc’s earnings last quarter?
Annovis Bio Inc released its earnings results on May 15, 2026. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.395 by -$0.235.
Is Annovis Bio Inc overvalued?
According to Wall Street analysts Annovis Bio Inc’s price is currently Undervalued.
Does Annovis Bio Inc pay dividends?
Annovis Bio Inc does not currently pay dividends.
What is Annovis Bio Inc’s EPS estimate?
Annovis Bio Inc’s EPS estimate is -0.46.
How many shares outstanding does Annovis Bio Inc have?
Annovis Bio Inc has 34,646,870 shares outstanding.
What happened to Annovis Bio Inc’s price movement after its last earnings report?
Annovis Bio Inc reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.395. Following the earnings report the stock price went down -3.286%.
Which hedge fund is a major shareholder of Annovis Bio Inc?
Currently, no hedge funds are holding shares in ANVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (568.45% Upside)
$12.50 (568.45% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.15%
12-Months-Change
Fundamentals
Return on Equity
-318.08%
Trailing 12-Months
Asset Growth
-39.25%
Trailing 12-Months
Company Description
Annovis Bio Inc
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
ANVS Stock 12 Month Forecast
Average Price Target
$12.50
▲(568.45% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―
Ownership Overview
13.92% Insiders
3.17% Mutual Funds
1.18% Other Institutional Investors
79.29% Public Companies and
Individual Investors